Analysts Are Bullish on These Consumer Goods Stocks: SQNS, SENS

By Ryan Adsit

There’s a lot to be optimistic about in the Consumer Goods sector as 2 analysts just weighed in on Sequans Communications S A (NYSE: SQNS) and Senseonics Holdings Inc (AMEX: SENS) with bullish sentiments.

Sequans Communications S A (NYSE: SQNS)

In a report released yesterday, Michael Walkley from Canaccord Genuity assigned a Buy rating to Sequans Communications S A (NYSE: SQNS), with a price target of $6. The company’s shares opened today at $3.11.

Walkley observed:

“We believe the module certification should accelerate product time to market for fast growing vertical market opportunities including vehicle telematics, security, and surveillance. We believe the certification is consistent with our expectations for ramping CAT-1 IoT related revenue during 2H17, as we estimate $15M of CAT-1 IoT related sales in 2017 increasing to $32M in C2018. This announcement ahead of MWC Americas follows the prior certification of the Calliope chipset on AT&T and other US carriers. In addition, Sequans recently introduced a tracker platform based on the integration of Sequans and ST technologies chipsets.”

According to, Walkley is a top 100 analyst with an average return of 19.3% and a 64.4% success rate. Walkley covers the Consumer Goods sector, focusing on stocks such as Digi International Inc, Powerwave Technologies, and Silicon Laboratories.

Currently, the analyst consensus on Sequans Communications S A is Strong Buy and the average price target is $5.13, representing a 65.0% upside.

In a report issued on September 7, Needham also assigned a Buy rating to the stock with a $4 price target.
Senseonics Holdings Inc (AMEX: SENS)

Canaccord Genuity analyst Kyle Rose maintained a Buy rating on Senseonics Holdings Inc (AMEX: SENS) yesterday and set a price target of $5. The company’s shares opened today at $3.14.

Rose observed:

“We maintain our BUY rating following Senseonics’ Eversense XL CE Mark approval. The approval of Eversense XL extends the wear-time of the Eversense system out to 180 days vs. the 90 days currently and is expected to start commercializing in the Q4/17 in Europe. We view the CE mark approval positively as it reduces a key barrier to adoption, the need for a patient to have a sensor inserted/ removed multiple times a year. Meanwhile, we are also updating our model to reflect the recent $28.7M follow-on offering.”

According to, Rose is a 5-star analyst with an average return of 12.6% and a 58.5% success rate. Rose covers the Healthcare sector, focusing on stocks such as Obalon Therapeutics Inc, Zimmer Biomet Holdings, and Stryker Corporation.

Senseonics Holdings Inc has an analyst consensus of Moderate Buy, with a price target consensus of $5.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.